Ojjaara
Ojjaara ingredients
| Active ingredient | Strength |
|---|---|
| Momelotinib Dihydrochloride Monohydrate | 200 mg/1, 150 mg/1, 100 mg/1 |
What Ojjaara is used for
The FDA lists the approved uses on the official label (below). In the EU, momelotinib is approved as Omjjara for:
Omjjara is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Ojjaara
- Generic name
- Momelotinib
- Made by
- GlaxoSmithKline LLC
- Forms
- Tablet
- Given
- Oral
- Drug class
- Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA216873
- On the US market since
- 2023
Official information
- Ojjaara prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Momelotinib)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Ojjaara?
Ojjaara (Momelotinib) is a cancer medicine made by GlaxoSmithKline LLC, approved by the US FDA.
What are the ingredients of Ojjaara?
Ojjaara contains Momelotinib Dihydrochloride Monohydrate (200 mg/1, 150 mg/1, 100 mg/1).
Is Ojjaara approved in Europe?
The same active substance is approved in the EU as Omjjara.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA